Building Better Medicines for Patients

Mission

At SalubrisBio, our mission is to develop first-in-class biologics that improve the health and quality of life for people living with complicated diseases.

We have the passion, commitment, and expertise needed to drive our assets through all phases of clinical development to deliver novel biologic therapies to patients. 

SalubrisBio is the first company in the world to bring a bispecific antibody into clinical trials in a cardiovascular indication. We endeavor to make this the first of many global innovation achievements.

Team

Sam Murphy

Chief Executive Officer

Sam Murphy

Sam Murphy

Chief Executive Officer

Sam is currently CEO of SalubrisBio and has worked at SalubrisBio since 2017. Prior to joining SalubrisBio, Sam worked for more than ten years in strategy consulting and transaction advisory services across several global firms, most recently as a Senior Principal at IMS (now IQVIA). Sam’s commercial strategy engagements encompassed 18 of the top 25 pharmaceutical companies, as well as numerous small and mid-sized biotech companies, with an emphasis on business development and market access. Sam completed his PhD in Virology at the University of Pennsylvania and his Post-Doctoral Fellowship in Gene Therapy and Translational Medicine at Children’s Hospital of Philadelphia. Sam currently also serves as Chairman of the Board at GO Therapeutics, Board Director at MedAlliance SA and Viracta Therapeutics, and a Board Observer at Mercator Medsystems. He is an author of >20 peer-reviewed publications and an inventor on several issued patents.


Shalabh Singhal

MD, Chief Medical Officer

Shalabh Singhal

Shalabh Singhal

MD, Chief Medical Officer

Shalabh Singhal, MD, is a board-certified cardiologist with more than a decade of drug development experience. He most recently served as VP and Development Lead at Bristol Myers Squibb, where he led development for multiple products, including SotyktuTM. Previously, he held cardiology positions at Mercer Bucks Cardiology, Community Health Network and Johnson Memorial Hospital. Dr. Singhal holds a Bachelor of Science in Chemistry from Canisius College, and an M.D. from Upstate Medical University. He completed his residency at Thomas Jefferson University and a fellowship at the University of Cincinnati.


Jijun Dong

Chief Scientific Officer

Jijun Dong

Jijun Dong

Chief Scientific Officer

Jijun Dong, PhD, is a seasoned drug hunter with over a decade of experience in biologics drug discovery and development within the cardiovascular, metabolism, and immune-oncology domains. Prior to joining SalubrisBio, Jijun was the VP of Biologics Research at Xilio Therapeutics, where she focused on complex biologic drug research for immune-oncology indications. She has held positions of increasing responsibility at various companies of different sizes, including Novartis and Alkermes Inc., where she covered activities ranging from early target validation to clinical candidate nomination and IND application. Jijun received her bachelor’s degree in chemistry from Peking University and her PhD in biochemistry from Emory University. She completed her postdoctoral training in Professor Susan Lindquist’s lab at the Whitehead Institute of Biomedical Research, where she studied protein misfolding and its relevance in normal biology, as well as in neurodegenerative diseases.


Stephen DiPalma

Interim Chief Financial Officer

Stephen DiPalma

Stephen DiPalma

Interim Chief Financial Officer

Mr. DiPalma is interim Chief Financial Officer and leads all financial and fiscal planning operations for SalubrisBio.

Mr. DiPalma has over 35 years of experience in financial management and capital formation in the life sciences industry. He is currently a managing director of Danforth Advisors, LLC, a financial consultancy that specializes in working with life sciences companies. Prior to and during his tenure at Danforth, Steve has served as Chief Financial Officer to a number of public companies, in addition to many private companies in various stages of development. Immediately prior to joining Danforth in 2014, he served as Chief Financial Officer at Forum Pharmaceuticals from 2009 to 2014. He holds a Bachelor of Science from the University of Massachusetts and a Master in Business Administration from Babson College.


Amanda McEwen

VP of Clinical Development and JK07 Program Lead

Amanda McEwen

Amanda McEwen

VP of Clinical Development and JK07 Program Lead

Amanda McEwen has over 14 years of experience in clinical research that spans work in academia, contract research organizations, and several Boston-area small-to-mid-size biotechnology companies. Throughout her career, Amanda has held roles of increasing responsibility within the Clinical/Regulatory Development space across a range of therapeutic areas including rare, neurodegenerative, respiratory, infectious, and metabolic diseases. Her experience includes a variety of therapeutic product types, including combination products, most notably a novel dry powder inhalation therapy to treat motor issues in Parkinson’s patients, Inbrija™, approved by the FDA and EMA. Amanda has a particular affinity for early phase work and has played pivotal roles in shepherding several programs from the bench to the clinic. In addition to her work in industry, Amanda serves as an adjunct faculty member for Northeastern University’s Master of Science in Regulatory Affairs for Drugs, Biologics, and Medical Devices, specializing in courses on the strategic and technical considerations for IND and NDA/MAA submissions and Pharmacovigilance regulations and best practices. Amanda holds a BA in Psychology from the College of the Holy Cross and a Master of Research Methods in Psychology degree from the University of York.


Dr. Jinhua Feng

VP, Head of CMC

Dr. Jinhua Feng

Dr. Jinhua Feng

VP, Head of CMC

Dr. Jinhua Feng joined SalubrisBio in 2017 as the Director of Research and Development. She quickly rose to Vice President, taking charge of analytical and formulation development in-house and outsourcing GMP manufacturing and QC testing. Prior to joining SalubrisBio, Dr. Feng spent more than fifteen years at MedImmune/AstraZeneca, where she concentrated on analytical method development, product characterization and structure/function relationship of monoclonal antibodies and fusion proteins, including Synagis and motavizumab. Her contributions were critical for understanding stabilizing immunoglobulin, photo-induced oxidation, charge variants, and color change of drug products. During her tenure, she also assumed CMC analytical leadership for the production of multiple pipeline programs, including the first monoclonal antibody program transferred to China and the first bispecific ADC program in the company.

Dr. Feng completed her doctorate in Analytical Chemistry from Utah State University and her Post-Doctoral Fellowship at Nebraska Center for Mass Spectrometry.


Naimish Pandya, MD

SVP, Oncology Clinical Lead

Naimish Pandya, MD

Naimish Pandya, MD

SVP, Oncology Clinical Lead

Naimish Pandya, MD, is a board-certified medical oncologist, physician-scientist, and immunotherapy drug developer with more than 17 years of progressive oncology and immuno-oncology clinical development experience. He is former faculty of the University of Maryland Greenebaum Comprehensive Cancer Center, where he led the gastroenterology oncology division and spearheaded multi-specialty-based clinical trials. Subsequently, Dr. Pandya transitioned his career full-time to industry and most recently served as Vice President & Head of Clinical Development at NexImmune, where he oversaw the company’s multi-antigen T cell therapy and progressed products into early clinical development. He previously held senior clinical leadership positions at Northern Biologics and MacroGenics. Dr. Pandya also served in varying roles and leadership at MedImmune/AZ, along with consulting leadership roles at GSK, Incyte and several start-up biotech companies. In these positions, he focused on developing and progressing various IO and targeted therapies, including small molecules, monoclonal antibodies, bispecifics, and oncolytic viruses in both solid tumors and heme malignancies.

Throughout his career, Dr. Pandya has developed oncologic and rheumatologic drug candidates and managed all phases of clinical trials. He has successfully taken many preclinical molecules through an IND launch and developed and executed numerous first-in-human Phase 1 trials. Similarly, he has led multiple global Phase 2 and Phase 3 clinical trials in oncology.

Dr. Pandya received his medical degree from Temple University and completed his oncology training at Thomas Jefferson University in Philadelphia.


Research Focus

We focus exclusively on developing novel, complex biologic therapeutics that have the potential to provide clinically meaningful improvements in disease burden and quality of life for patients with significant unmet medical needs.

Our disease targets are in cardiovascular disease, oncology, and neurodegenerative disease, three leading causes of death in the world today.

US Leading Causes of Death (2021)

US Leading Causes of Death (2021)

Pipeline Overview

Pipeline overview 241123

History

SalubrisBio was founded in August 2016 as a wholly-owned subsidiary of the China-based pharmaceutical company Salubris Pharmaceuticals Co. Ltd. (www.salubris.com). SalubrisBio is an innovation-focused biotech with pioneering research and development programs. Headquartered in the US, SalubrisBio reflects Salubris Pharmaceuticals’ commitment to innovation and expansion into the global market and retains the core philosophy of developing therapeutics for large patient populations with significant unmet needs.